ACW third positive XanaMIA trial data committee review
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Actinogen Medical Limited announces the receipt of a positive recommendation from the Data Monitoring Committee for the XanaMIA trial, which focuses on Alzheimer's disease treatment. The committee reviewed safety data from trial participants and concluded that the trial should continue without amendments. Final trial results are anticipated later this year, with the company expressing confidence in the potential of Xanamem as a treatment option.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Actinogen Medical Limited on 6ix
Story so far
Earlier from Actinogen Medical
- Actinogen receives positive EMA scientific advice aligned with prior FDA guidance for its Alzheimer’s disease program
- Actinogen receives positive scientific advice from EMA
- Correction-March2026 quarterly activity report & Appendix 4C
- Actinogen commences open-label phase of XanaMIA Alzheimer’s trial and provides business update
- ACW XanaMIA Alzheimers open label trial commences
Later from Actinogen Medical
- Xanamem depression trial published in British J Psychiatry
- June 2026 Quarterly activity report & Appendix 4C
- ACW Appendix 4E and 2026 annual report
- ACW FY2026 results and outlook
- ACW unlisted options fully underwritten
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical